NCT05903066Completed
TRansmural hEaliNg Definition in CroHn's Disease (TRENCH 1)
TRansmural hEaliNg Definition in CroHn's Disease - The TRENCH1 Study
Source: ClinicalTrials.gov · Last updated 4 Nov 2026
Brief summary (registry, in English)
Multicenter prospective cross-sectional study of CD patients, its aim is the construction of an objective and reproducible system for evaluation of Transmural healing in Crohn's Disease (CD). Primary objective : Objective definition of depth or grade of transmural healing in relation to radiologic signs observed during Magnetic Resonance Enterography (MRE) in CD
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 320 (actual)
- First submitted
- 5 Jun 2023
- Start date
- 28 Sept 2023
- Primary completion date
- 19 Sept 2025
- Lead sponsor
- Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
- Diseases
- Crohn's disease
- NCT number
- NCT05903066
What you commit to
- Study type: Observational
- Participants enrolled: 320
- From 28 Sept 2023 to the primary completion date, 19 Sept 2025
- 13 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- MRE images of poor quality, based on previously defined criteria
Other illness
- Isolated perianal disease without luminal location
Other
- Pregnancy during the study
- People unable to give consent (because of their physical or mental state)
- Absence of written consent
- Ulcerative colitis or unclassified IBD
- Specific postsurgical settings: ileoanal anastomosis, ileostomy or colostomy.
- Less than 3 evaluable ileocolic segments or more than 3 resected ileocolonic segments (not counting ileocecal valve)
- Severe obstructive symptoms
- Symptomatic intra-abdominal abscess
- Contraindication for MRI
Who the study is looking for
- ≥ 18 years of age
- Patient diagnosed with CD for more than 6 months with histological confirmation available in his medical record.
- Indication for MRE based on routine clinical practice validated by the treating physician
- Any CD treatment will be authorized, such as biologicals (infliximab, adalimumab, vedolizumab, ustekinumab…), or immunomodulators (azathioprine, 6-mercaptopurine, methotrexate…).
- The subjects sign and date a written, informed consent form and any required privacy authorization prior to the initiation of the study.
- A subject can be enrolled into the study only if the grade of TH (assessed by the LRP) corresponding to the subject is not already fulfilled.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (13)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU de Liège | Liège | Belgium | Unknown status |
| CHU Amiens-Picardie - Site Sud | Amiens | France | Unknown status |
| CHU de Bordeaux - Hopital Haut Leveque | Bordeaux | France | Unknown status |
| APHP - Hopital Ambroise Pare | Boulogne-Billancourt | France | Unknown status |
| CHU de Clermont-Ferrand - Hôpital d'Estaing | Clermont-Ferrand | France | Unknown status |
| CHRU de Lille - Hopital Claude Huriez | Lille | France | Unknown status |
| CHU Limoges - Dupuytren | Limoges | France | Unknown status |
| AP-HM Hôpital Nord | Marseille | France | Unknown status |
| CHU de Montpellier Hôpital Saint Eloi | Montpellier | France | Unknown status |
| CHU de Nantes | Nantes | France | Unknown status |
| CHU de Nîmes - HOPITAL CAREMEAU | Nîmes | France | Unknown status |
| Hospices Civils de Lyon | Pierre-Bénite | France | Unknown status |
| CHU Rennes - Hopital Pontchaillou | Rennes | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.